nach oben

Archives of Dermatological Research

Erschienen in:

01.05.2024 | REVIEW

Herpes zoster infection in pregnancy: features and consequences

verfasst von: Amit Singal, Robert A. Schwartz, Chinmoy Bhate

Erschienen in: Archives of Dermatological Research | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Herpes (varicella) zoster (HZ) infection occurs in 4 people per 1000 in the general US population (irrespective of prior varicella infection and vaccination status) each year and has been the subject of scientific inquiry for decades. The consequences of infection are myriad and may depend on the dermatome of involvement as well as host factors such as age, comorbidities, prior treatment or immunization, and immunologic status. Pregnancy is associated with an altered immune and hormonal status in the mother. While maternal HZ infection during pregnancy is not uncommon, the implications for both mother and child are not well established, although multiple studies of perinatal maternal HZ infection suggest no intrauterine transmission to the fetus. We review the current literature on herpes zoster infection in pregnancy, including epidemiology, diagnosis, potential immunologic sequelae, and strategies for prevention and treatment.

Centers for Disease Control and Prevention (CDC) (2020) Shingles (Herpes Zoster). In: Shingles home. Avaliable via https://www.cdc.gov/shingles/hcp/clinical-overview.html#:~:text=Disease%20Rates,-An%20estimated%20one&text=The%20incidence%20for%20herpes%20zoster,per%20100%20U.S.%20population%20annually. Accessed Mar 2024

Schmader K (2018) Herpes zoster. Ann Intern Med 169(3):itc19–itc31. https://doi.org/10.7326/aitc201808070CrossRefPubMed

Schafer R, Davis M, Phillippi JC (2019) Herpes zoster in pregnancy. J Midwifery Womens Health 64(2):230–235. https://doi.org/10.1111/jmwh.12953CrossRefPubMed

Enders G, Miller E (2000) Varicella and herpes zoster in pregnancy and the newborn. In: Arvin AM, Gershon AA (eds) Varicella-zoster virus: virology and clinical management. Cambridge University Press, Cambridge, pp 317–348CrossRef

Kennedy PGE, Mogensen TH, Cohrs RJ (2021) Recent issues in varicella-zoster virus latency. Viruses. https://doi.org/10.3390/v13102018CrossRefPubMedPubMedCentral

Kennedy PGE, Gershon AA (2018) Clinical features of varicella-zoster virus infection. Viruses. https://doi.org/10.3390/v10110609CrossRefPubMedPubMedCentral

Gershon AA et al (2015) Varicella zoster virus infection. Nat Rev Dis Primers 1:15016. https://doi.org/10.1038/nrdp.2015.16CrossRefPubMedPubMedCentral

Centers for Disease Control and Prevention (CDC) (2021) Zoster. In: Epidemiology and prevention of vaccine-preventable diseases. Avaliable via https://www.cdc.gov/vaccines/pubs/pinkbook/herpes-zoster.html#:~:text=The%20first%20vaccine%20to%20reduce,the%20United%20States%20in%202006. Accessed Mar 2024

Harpaz R, Ortega-Sanchez I, Seward J (2008) Advisory committee on immunization practices centers for disease C, prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57(RR-5):1–30PubMed

10.

Gershon M, Gershon A (2018) Varicella-zoster virus and the enteric nervous system. J Infect Dis 218(suppl_2):S113-s119. https://doi.org/10.1093/infdis/jiy407CrossRefPubMedPubMedCentral

11.

Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ (2000) Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 342(9):635–645. https://doi.org/10.1056/nejm200003023420906CrossRefPubMed

12.

Reynolds MA, Kruszon-Moran D, Jumaan A, Schmid DS, McQuillan GM (2010) Varicella seroprevalence in the US: data from the National Health and Nutrition Examination Survey, 1999–2004. Public Health Rep 125(6):860–869. https://doi.org/10.1177/003335491012500613CrossRefPubMedPubMedCentral

13.

van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B (2021) A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother 17(6):1714–1732. https://doi.org/10.1080/21645515.2020.1847582CrossRefPubMedPubMedCentral

14.

Mor G, Cardenas I (2010) The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 63(6):425–433. https://doi.org/10.1111/j.1600-0897.2010.00836.xCrossRefPubMedPubMedCentral

15.

Marra F, Parhar K, Huang B, Vadlamudi N (2020) Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis 7(1):ofaa005. https://doi.org/10.1093/ofid/ofaa005CrossRefPubMedPubMedCentral

16.

Lin WC, Wei JC (2023) Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2 442 686 patients. J Med Virol 95(7):e28903. https://doi.org/10.1002/jmv.28903CrossRefPubMed

17.

Chen YC et al (2023) Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2 442 686 patients. J Med Virol 95(4):e28745. https://doi.org/10.1002/jmv.28745CrossRefPubMed

18.

Akpandak I, Miller DC, Sun Y, Arnold BF, Kelly JD, Acharya NR (2022) Assessment of herpes zoster risk among recipients of COVID-19 vaccine. JAMA Netw Open 5(11):e2242240–e2242240. https://doi.org/10.1001/jamanetworkopen.2022.42240CrossRefPubMedPubMedCentral

19.

Saguil A, Kane S, Mercado M, Lauters R (2017) "Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Phys 96(10):656–663

20.

Russell LK (1992) Management of varicella-zoster virus infection during pregnancy and the peripartum. J Nurse Midwifery 37(1):17–24. https://doi.org/10.1016/0091-2182(92)90018-xCrossRefPubMed

21.

Sampathkumar P, Drage LA, Martin DP (2009) Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 84(3):274–280. https://doi.org/10.1016/s0025-6196(11)61146-4CrossRefPubMedPubMedCentral

22.

Nanthakumar MP, Sood A, Ahmed M, Gupta J (2021) Varicella zoster in pregnancy. Eur J Obstet Gynecol Reprod Biol 258:283–287. https://doi.org/10.1016/j.ejogrb.2021.01.009CrossRefPubMed

23.

Paryani SG, Arvin AM (1986) Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 314(24):1542–1546. https://doi.org/10.1056/nejm198606123142403CrossRefPubMed

24.

Mouly F et al (1997) Prenatal diagnosis of fetal varicella-zoster virus infection with polymerase chain reaction of amniotic fluid in 107 cases. Am J Obstet Gynecol 177(4):894–898CrossRefPubMed

25.

Lamont RF et al (2011) Varicella-zoster virus (chickenpox) infection in pregnancy. BJOG 118(10):1155–1162. https://doi.org/10.1111/j.1471-0528.2011.02983.xCrossRefPubMedPubMedCentral

26.

Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M (1994) Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343(8912):1548–1551. https://doi.org/10.1016/s0140-6736(94)92943-2CrossRefPubMed

27.

Blumental S, Lepage P (2019) Management of varicella in neonates and infants. BMJ Paediatr Open 3(1):e000433. https://doi.org/10.1136/bmjpo-2019-000433CrossRefPubMedPubMedCentral

28.

Sauerbrei A, Wutzler P (2001) Neonatal varicella. J Perinatol 21(8):545–549. https://doi.org/10.1038/sj.jp.7210599CrossRefPubMed

29.

Centers for Disease Control and Prevention (CDC) (2021) Chickenpox vaccination: what everyone should know. In: Vaccines and preventable diseases. Avaliable via https://www.cdc.gov/vaccines/vpd/varicella/public/index.html. Accessed Mar 2024

30.

ProQuad® [Package insert] (2005) Merck & Co., Inc., Rahway, NJ, USA

31.

Singh T, Otero CE, Li K, Valencia SM, Nelson AN, Permar SR (2020) Vaccines for perinatal and congenital infections-how close are we? Front Pediatr 8:569. https://doi.org/10.3389/fped.2020.00569CrossRefPubMedPubMedCentral

32.

M. The Centers for Disease Control and Prevention (CDC) (2021) MMRV (Measles, Rubella & Varicella) VIS. In: Vaccine information statements (VISs). Available via https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmrv.html. Accessed Mar 2024

33.

Gershon AA, Gershon MD, Shapiro ED (2021) Live attenuated varicella vaccine: prevention of varicella and of zoster. J Infect Dis 224(Supplement_4):S387–S397. https://doi.org/10.1093/infdis/jiaa573CrossRefPubMedPubMedCentral

34.

Weinmann S et al (2013) Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis 208(11):1859–1868. https://doi.org/10.1093/infdis/jit405CrossRefPubMed

35.

Hardy I, Gershon AA, Steinberg SP, LaRussa P (1991) The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 325(22):1545–1550. https://doi.org/10.1056/nejm199111283252204CrossRefPubMed

36.

American Society for Reproductive Medicine; American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice (2019) Prepregnancy counseling: committee opinion no. 762. Fertil Steril 111(1):32-42. https://doi.org/10.1016/j.fertnstert.2018.12.003. (PMID: 30611411)

37.

CDC (2022) Guidelines for vaccinating pregnant women. In: pregnancy and vaccination. Available via https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html#18. Accessed Mar 2024

38.

Willis ED, Marko AM, Rasmussen SA, McGee M, Broder KR, Marin M (2022) Merck/Centers for disease control and prevention varicella vaccine pregnancy registry: 19-year summary of data from inception through closure, 1995–2013. J Infect Dis 226(Supplement_4):S441-s449. https://doi.org/10.1093/infdis/jiac277CrossRefPubMed

39.

Hayward K, Cline A, Stephens A, Street L (2018) Management of herpes zoster (shingles) during pregnancy. J Obstet Gynaecol 38(7):887–894. https://doi.org/10.1080/01443615.2018.1446419CrossRefPubMed

40.

Park TH, Chang CH (2012) Keloid recurrence in pregnancy. Aesthetic Plast Surg 36(5):1271–1272. https://doi.org/10.1007/s00266-012-9947-5CrossRefPubMed

41.

Verma SB, Wollina U (2013) Herpes zoster in pregnancy leading to keloids and post herpetic neuralgia: a double whammy? Indian Dermatol Online J 4(2):158–159. https://doi.org/10.4103/2229-5178.110646CrossRefPubMedPubMedCentral

42.

Casanova Román G, Reyna Figueroa J, Figueroa Damián R, Ortiz Ibarra J (2004) Herpes zoster in immunocompetent pregnant women and their perinatal outcome. Ginecol Obstet Mex 72:63–67PubMed

43.

Miller E, Cradock-Watson JE, Ridehalgh MK (1989) Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 2(8659):371–373. https://doi.org/10.1016/s0140-6736(89)90547-3CrossRefPubMed

44.

Miller E, Marshall R, Vurdien J (1993) Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 4(4):222–230CrossRef

45.

Quenby S et al (2021) Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet 397(10285):1658–1667. https://doi.org/10.1016/s0140-6736(21)00682-6CrossRefPubMed

46.

(2023) Herpes zoster (Shingles). In: Mother to baby | Fact Sheets [Internet]. Organization of teratology information specialists (OTIS), Brentwood (TN), 1994–. (PMID: 35952020)

47.

Higa K, Dan K, Manabe H (1987) Varicella-zoster virus infections during pregnancy: hypothesis concerning the mechanisms of congenital malformations. Obstet Gynecol 69(2):214–222PubMed

48.

Dworkin RH et al (2007) Recommendations for the management of herpes zoster. Clin Infect Dis 44(Suppl 1):S1-26. https://doi.org/10.1086/510206CrossRefPubMed

49.

Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB (2000) Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 182(1 Pt 1):159–163. https://doi.org/10.1016/s0002-9378(00)70506-0CrossRefPubMed

50.

Stone KM et al (2004) Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res A Clin Mol Teratol 70(4):201–207. https://doi.org/10.1002/bdra.20013CrossRefPubMed

51.

Pasternak B, Hviid A (2010) Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304(8):859–866. https://doi.org/10.1001/jama.2010.1206CrossRefPubMed

52.

LIDODERM (Lidocaine Patch 5%) [Package insert] (2014) Endo Pharmaceuticals Inc., Malvern, PA

53.

Kim JY, Ko YR, Sim SE, Oh S, Lee MH, Park HJ (2020) Safe drug treatment and procedure for herpes zoster in pregnancy: a case report. Chin Med J (Engl) 133(16):1999–2000. https://doi.org/10.1097/cm9.0000000000000927CrossRefPubMed

54.

Sadati MS, Ahrari I (2014) Severe herpes zoster neuralgia in a pregnant woman treated with acetaminophen. Acta Med Iran 52(3):238–239PubMed

55.

Wong JW, Chin JM, Schlueter RJ (2018) Shingles in pregnancy: an elusive case of left upper quadrant abdominal pain. Hawaii J Med Public Health 77(8):179–182PubMedPubMedCentral

56.

Stanley AY, Durham CO, Sterrett JJ, Wallace JB (2019) Safety of over-the-counter medications in pregnancy. MCN Am J Matern Child Nurs 44(4):196–205. https://doi.org/10.1097/nmc.0000000000000537CrossRefPubMed

57.

FDA (2015) FDA drug safety communication: FDA has reviewed possible risks of pain medicine use during pregnancy. In: Drug safety and avaliability. Avaliable via: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-has-reviewed-possible-risks-pain-medicine-use-during-pregnancy. Accessed Mar 2024

58.

NEURONTIN® (gabapentin) [package insert]. New York, NY: Pfizer Pharmaceuticals, Inc. December 2020

59.

LYRICA (pregabalin) [package insert]. New York, NY: Pfizer Pharmaceuticals Inc. 2020

60.

Patorno E et al (2020) Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US medicaid analytic eXtract dataset. PLoS Med 17(9):e1003322. https://doi.org/10.1371/journal.pmed.1003322CrossRefPubMedPubMedCentral

61.

Mostacci B, Poluzzi E, D’Alessandro R, Cocchi G, Tinuper P (2018) Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. J Neurol Neurosurg Psychiatry 89(2):223–224. https://doi.org/10.1136/jnnp-2017-316143CrossRefPubMed

62.

Andrade C (2018) Safety of pregabalin in pregnancy. J Clin Psychiatry. https://doi.org/10.4088/JCP.18f12568CrossRefPubMed

63.

CDC (2022) Clinical considerations for use of recombinant zoster vaccine (RZV, Shingrix) in immunocompromised adults aged ≥ 19 years. In: Shingles (Herpes Zoster). Available via https://www.cdc.gov/shingles/vaccination/immunocompromised-adults.html. Accessed Mar 2024

Titel: Herpes zoster infection in pregnancy: features and consequences
verfasst von: Amit Singal
Robert A. Schwartz
Chinmoy Bhate
Publikationsdatum: 01.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Dermatological Research / Ausgabe 4/2024
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-024-02842-3

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Characterization of alopecia clinical trials: an analysis of trials registered on clinicaltrials.gov

Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups

Cracking the code: unveiling the nexus between atopic dermatitis and addictive behavior: a cross-sectional exploration of risk factors

Review of the application of the most current sophisticated image processing methods for the skin cancer diagnostics purposes

Topical steroids or emollients: does order matter?